dc.contributor
Institut Català de la Salut
dc.contributor
[Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J] Unitat de Tumors Gastrointestinals i Endocrins, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Garcia Alvarez, Alejandro
dc.contributor.author
Hernando Cubero, Jorge
dc.contributor.author
Carmona Alonso, Ana
dc.contributor.author
Capdevila Castillon, Jaume
dc.date.accessioned
2023-11-08T10:20:34Z
dc.date.available
2023-11-08T10:20:34Z
dc.date.issued
2022-10-26T10:08:13Z
dc.date.issued
2022-10-26T10:08:13Z
dc.date.issued
2022-08-05
dc.identifier
Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J. What is the status of immunotherapy in thyroid neoplasms? Front Endocrinol. 2022 Aug 5;13:929091.
dc.identifier
https://hdl.handle.net/11351/8342
dc.identifier
10.3389/fendo.2022.929091
dc.identifier
000842917900001
dc.identifier.uri
https://hdl.handle.net/11351/8342
dc.description.abstract
Immunotherapy; Thyroid neoplasms; Tumor mutational burden
dc.description.abstract
Inmunoterapia; Neoplasias de la tiroides; Carga mutacional tumoral
dc.description.abstract
Immunoteràpia; Neoplàsies de les tiroides; Càrrega mutacional tumoral
dc.description.abstract
Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of potential predictive biomarkers of response and efficacy of immunotherapy in thyroid neoplasms. Programmed death-ligand 1 (PD-L1) staining by immunohistochemistry has shown higher expression in anaplastic thyroid cancer (ATC) compared to other subtypes. The tumor mutational burden in thyroid neoplasms is low but seems to be higher in ATC. Immune infiltrates in the tumor microenvironment (TME) differ between the different thyroid neoplasm subtypes. In general, differentiated thyroid cancer (DTC) has a higher number of tumor-associated lymphocytes and regulatory T cells (Tregs), while ATC and medullary thyroid cancer (MTC) display a high density of tumor-associated macrophages (TAMs). Nevertheless, results from clinical trials with immunotherapy as monotherapy or combinations have shown limited efficacy. Further investigation into new strategies aside from anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)/programmed death 1 (PD-1)/PD-L1 antibodies, validation of predictive biomarkers, and better population selection for clinical trials in thyroid neoplasms is more than needed in the near future.
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Frontiers in Endocrinology;13
dc.relation
https://doi.org/10.3389/fendo.2022.929091
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Tiroide - Càncer - Tractament
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.title
What is the status of immunotherapy in thyroid neoplasms?
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
